Cargando…
Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601801/ https://www.ncbi.nlm.nih.gov/pubmed/33007918 http://dx.doi.org/10.3390/nu12103004 |
_version_ | 1783603518674829312 |
---|---|
author | Röhling, Martin Martin, Katharina Ellinger, Sabine Schreiber, Michael Martin, Stephan Kempf, Kerstin |
author_facet | Röhling, Martin Martin, Katharina Ellinger, Sabine Schreiber, Michael Martin, Stephan Kempf, Kerstin |
author_sort | Röhling, Martin |
collection | PubMed |
description | Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily insulin levels for long-term weight reduction in overweight or obesity. Employees were randomized into a starting intervention group (SI, n = 15) or waiting list control group (WL, n = 15). SAMMAS consisted of group-based seminars, low-carbohydrate nutrition including formula diet, continuous glucose monitoring, telemetric monitoring, and telemedical coaching. Both groups received telemetric devices at baseline. Intention-to-treat analyses were performed after 12, 26, and 52 weeks. The estimated treatment difference in weight reduction after 12 weeks, which is the primary endpoint of the study, showed a pronounced effect in favour of SI (−6.3 kg with (95% confidence interval) (−7.4; −4.5) (p < 0.001)) after 12 weeks. Furthermore, SI improved fasting blood glucose, HbA1c, quality of life, fasting insulin, blood pressure, and eating behaviour (all p < 0.05) in the within-group analysis, while WL did not. After 26 and 52 weeks, weight reduction could be maintained in the whole group (both groups together) by −6.7 kg (−9.5; −3.8) (p < 0.001) and −6.1 kg (−9.2; −2.7) (p < 0.01). SAMMAS supports clinically relevant weight reduction and long-term weight loss maintenance in individuals with overweight or obesity. |
format | Online Article Text |
id | pubmed-7601801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76018012020-11-01 Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial Röhling, Martin Martin, Katharina Ellinger, Sabine Schreiber, Michael Martin, Stephan Kempf, Kerstin Nutrients Article Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily insulin levels for long-term weight reduction in overweight or obesity. Employees were randomized into a starting intervention group (SI, n = 15) or waiting list control group (WL, n = 15). SAMMAS consisted of group-based seminars, low-carbohydrate nutrition including formula diet, continuous glucose monitoring, telemetric monitoring, and telemedical coaching. Both groups received telemetric devices at baseline. Intention-to-treat analyses were performed after 12, 26, and 52 weeks. The estimated treatment difference in weight reduction after 12 weeks, which is the primary endpoint of the study, showed a pronounced effect in favour of SI (−6.3 kg with (95% confidence interval) (−7.4; −4.5) (p < 0.001)) after 12 weeks. Furthermore, SI improved fasting blood glucose, HbA1c, quality of life, fasting insulin, blood pressure, and eating behaviour (all p < 0.05) in the within-group analysis, while WL did not. After 26 and 52 weeks, weight reduction could be maintained in the whole group (both groups together) by −6.7 kg (−9.5; −3.8) (p < 0.001) and −6.1 kg (−9.2; −2.7) (p < 0.01). SAMMAS supports clinically relevant weight reduction and long-term weight loss maintenance in individuals with overweight or obesity. MDPI 2020-09-30 /pmc/articles/PMC7601801/ /pubmed/33007918 http://dx.doi.org/10.3390/nu12103004 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Röhling, Martin Martin, Katharina Ellinger, Sabine Schreiber, Michael Martin, Stephan Kempf, Kerstin Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial |
title | Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial |
title_full | Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial |
title_fullStr | Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial |
title_full_unstemmed | Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial |
title_short | Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial |
title_sort | weight reduction by the low-insulin-method—a randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601801/ https://www.ncbi.nlm.nih.gov/pubmed/33007918 http://dx.doi.org/10.3390/nu12103004 |
work_keys_str_mv | AT rohlingmartin weightreductionbythelowinsulinmethodarandomizedcontrolledtrial AT martinkatharina weightreductionbythelowinsulinmethodarandomizedcontrolledtrial AT ellingersabine weightreductionbythelowinsulinmethodarandomizedcontrolledtrial AT schreibermichael weightreductionbythelowinsulinmethodarandomizedcontrolledtrial AT martinstephan weightreductionbythelowinsulinmethodarandomizedcontrolledtrial AT kempfkerstin weightreductionbythelowinsulinmethodarandomizedcontrolledtrial |